Continuing its trend started last year, Novartis AG is offering another $500-million-plus total package for biotech innovation, this time licensing development and commercialization rights to BCR-ABL inhibitors from SGX Pharmaceuticals Inc. (BioWorld Today)
Encysive Pharmaceuticals Inc. lost almost half its stock value Monday on news that the FDA may require additional clinical trial work for the pulmonary arterial hypertension drug Thelin. (BioWorld Today)
Since its founding in 1997, German company Noxxon Pharma AG has flown low, working to develop products based on its Spiegelmer technology. (BioWorld Today)
News that Nabi Biopharmaceuticals intends to continue development of its Gram-positive programs - which includes the lead drugs StaphVAX and Altastaph - restored investor hopes Wednesday, as the company’s stock climbed 15.8 percent. (BioWorld Today)
The Medicines and Healthcare products Regulatory Agency (MHRA) in London is investigating the hospitalization of six men who took part in a Phase I trial of TGN1412, an immunomodulatory humanized agonistic anti-CD28 monoclonal antibody designed to treat chronic inflammatory conditions and leukemia. (BioWorld International)
A research collaboration that started in August 2003 came full circle this week when French company NicOx SA granted Merck & Co. Inc. exclusive worldwide development and marketing rights to nitric oxide-donating drugs for hypertension. (BioWorld Today)
About 18 months ago, South San Francisco-based Exelixis Inc. made a $25.7 million investment when it acquired three preclinical programs through its buyout of X-Ceptor Therapeutics Inc. (BioWorld Today)
